Skip NavigationSkip to Content

Data imbalance in drug response prediction: multi-objective optimization approach in deep learning setting

  1. Author:
    Narykov, Oleksandr [ORCID]
    Zhu, Yitan
    Brettin, Thomas
    Evrard,Yvonne
    Partin, Alexander
    Xia, Fangfang [ORCID]
    Shukla, Maulik
    Vasanthakumari, Priyanka
    Doroshow, James H
    Stevens, Rick L [ORCID]
  2. Author Address

    Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 S Cass Ave, Lemont, IL 60439, United States., Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, 8560 Progress Drive, Frederick, MD 21702, United States., Developmental Therapeutics Branch, National Cancer Institute, 31 Center Dr, Bethesda, MD 20892, United States., Department of Computer Science, The University of Chicago, 5730 S Ellis Ave, Chicago, IL 60637, United States.,
    1. Year: 2025
    2. Date: Mar 04
  1. Journal: Briefings in Bioinformatics
    1. 26
    2. 2
  2. Type of Article: Article
  3. Article Number: bbaf134
  1. Abstract:

    Drug response prediction (DRP) methods tackle the complex task of associating the effectiveness of small molecules with the specific genetic makeup of the patient. Anti-cancer DRP is a particularly challenging task requiring costly experiments as underlying pathogenic mechanisms are broad and associated with multiple genomic pathways. The scientific community has exerted significant efforts to generate public drug screening datasets, giving a path to various machine learning models that attempt to reason over complex data space of small compounds and biological characteristics of tumors. However, the data depth is still lacking compared to application domains like computer vision or natural language processing domains, limiting current learning capabilities. To combat this issue and improves the generalizability of the DRP models, we are exploring strategies that explicitly address the imbalance in the DRP datasets. We reframe the problem as a multi-objective optimization across multiple drugs to maximize deep learning model performance. We implement this approach by constructing Multi-Objective Optimization Regularized by Loss Entropy loss function and plugging it into a Deep Learning model. We demonstrate the utility of proposed drug discovery methods and make suggestions for further potential application of the work to achieve desirable outcomes in the healthcare field. © The Author(s) 2025. Published by Oxford University Press.

    See More

External Sources

  1. DOI: 10.1093/bib/bbaf134
  2. PMID: 40178282
  3. PMCID: PMC11966611
  4. PII : 8104856

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel